Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

2209 ARTÍCULOS , VIENDO DEL 451 AL 465

The distribution of phosphorylated tau in spinal cords of Alzheimer's disease and non-demented individuals

Dugger BN, Hidalgo JA, Chiarolanza G, Mariner M, Henry-Watson J, Sue LI, Beach TG.

J Alzheimers Dis. 2013;34(2):529-36. doi: 10.3233/JAD-121864.

[Comparative study of eating behavior in elderly patients with Alzheimer's disease and vascular dementia: a first report. - Comparison of disturbed eating behavior - ]

Edahiro A, Hirano H, Yamada R, Chiba Y, Watanabe Y.

Nihon Ronen Igakkai Zasshi. 2013;50(5):651-60. doi: 10.3143/geriatrics.50.651.

Genetics of familial and sporadic Alzheimer's disease

Piaceri I, Nacmias B, Sorbi S.

Front Biosci (Elite Ed). 2013 Jan 1;5(1):167-77. doi: 10.2741/e605.

Role of WWOX/WOX1 in Alzheimer's disease pathology and in cell death signaling

Teng CC, Yang YT, Chen YC, Kuo YM, Sze CI.

Front Biosci (Schol Ed). 2013 Jan 1;5(1):72-85. doi: 10.2741/s358.

Structural networks in Alzheimer's disease

Reid AT, Evans AC.

Eur Neuropsychopharmacol. 2013 Jan;23(1):63-77. doi: 10.1016/j.euroneuro.2012.11.010. Epub 2013 Jan 5.

Immunotherapy against amyloid pathology in Alzheimer's disease

Galimberti D, Ghezzi L, Scarpini E.

J Neurol Sci. 2013 Oct 15;333(1-2):50-4. doi: 10.1016/j.jns.2012.12.013. Epub 2013 Jan 5.

Passive immunotherapy for Alzheimer's disease: what have we learned, and where are we headed?

Aisen PS, Vellas B.

J Nutr Health Aging. 2013 Jan;17(1):49-50. doi: 10.1007/s12603-013-0001-3.

Coupled cognitive and functional change in Alzheimer's disease and the influence of depressive symptoms

Zahodne LB, Devanand DP, Stern Y.

J Alzheimers Dis. 2013;34(4):851-60. doi: 10.3233/JAD-121921.

Alzheimer's disease modeling: ups, downs, and perspectives for human induced pluripotent stem cells

Wojda U, Kuznicki J.

J Alzheimers Dis. 2013;34(3):563-88. doi: 10.3233/JAD-121984.

Shared cognitive and behavioral impairments in epilepsy and Alzheimer's disease and potential underlying mechanisms

Chin J, Scharfman HE.

Epilepsy Behav. 2013 Mar;26(3):343-51. doi: 10.1016/j.yebeh.2012.11.040. Epub 2013 Jan 13.

The neurodegeneration in Alzheimer disease and the prion protein

Forloni G, Sclip A, Borsello T, Balducci C.

Prion. 2013 Jan-Feb;7(1):60-5. doi: 10.4161/pri.23286. Epub 2013 Jan 1.

TOMM40 and APOE: Requirements for replication studies of association with age of disease onset and enrichment of a clinical trial

Roses AD, Lutz MW, Crenshaw DG, Grossman I, Saunders AM, Gottschalk WK.

Alzheimers Dement. 2013 Mar;9(2):132-6. doi: 10.1016/j.jalz.2012.10.009. Epub 2013 Jan 18.

Safety and pharmacology of ponezumab (PF-04360365) after a single 10-minute intravenous infusion in subjects with mild to moderate Alzheimer disease

Burstein AH, Zhao Q, Ross J, Styren S, Landen JW, Ma WW, McCush F, Alvey C, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):8-13. doi: 10.1097/WNF.0b013e318279bcfa.

Safety and pharmacology of a single intravenous dose of ponezumab in subjects with mild-to-moderate Alzheimer disease: a phase I, randomized, placebo-controlled, double-blind, dose-escalation study

Landen JW, Zhao Q, Cohen S, Borrie M, Woodward M, Billing CB Jr, Bales K, Alvey C, McCush F, Yang J, Kupiec JW, Bednar MM.

Clin Neuropharmacol. 2013 Jan-Feb;36(1):14-23. doi: 10.1097/WNF.0b013e31827db49b.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias